Company news

Actinogen Medical Limited news in 2026

Actinogen Medical Limited's news releases, calls and decks from 2026, newest first.

View company

ACW Bioshares presentation, strong cortisol rationale

August 5, 2026

Application for quotation of securities - ACW

August 4, 2026

ACW webinar on the future of Alzheimers treatment

August 4, 2026

June 2026 Quarterly activity report & Appendix 4C

July 29, 2026

Application for quotation of securities - ACW

July 28, 2026

Xanamem depression trial published in British J Psychiatry

July 19, 2026

ACW third positive XanaMIA trial data committee review

June 17, 2026

Actinogen receives positive EMA scientific advice aligned with prior FDA guidance for its Alzheimer’s disease program

May 28, 2026

Actinogen receives positive scientific advice from EMA

May 27, 2026

Correction-March2026 quarterly activity report & Appendix 4C

April 28, 2026

Actinogen commences open-label phase of XanaMIA Alzheimer’s trial and provides business update

April 1, 2026

ACW XanaMIA Alzheimers open label trial commences

March 31, 2026

ACW successfully completes $16.8m Placement and SPP

February 26, 2026

ACW HY26 results - XanaMIA pivotal Alzheimers trial progress

February 25, 2026

Actinogen HY2025 financial report and Appendix 4D

February 25, 2026

ACW receives further $1.9m FY2025 R&D rebate from ATO

February 10, 2026

Actinogen receives positive Interim Analysis recommendation from its independent Data Monitoring Committee to continue the XanaMIA pivotal Alzheimer’s disease trial

February 2, 2026

ACW secures funding beyond XanaMIA AD trial final results

February 1, 2026

ACW December 2025 quarterly activity report & Appendix 4C

January 29, 2026

Continuation of Trading Halt

January 29, 2026

ACW positive XanaMIA Interim Analysis outcome

January 29, 2026

Trading Halt

January 28, 2026

Actinogen secures $4.3m of non-dilutive R&D tax funding

January 26, 2026

← Newer news releases

Decks in 2026